Winston & Strawn represented Roth Capital Partners, LLC, sole manager, in a US$69,000,000 underwritten offering of the common stock of China-Biotics, Inc. In the offering, China-Biotics drew down shares from its previously filed shelf registration statement on Form S-3. China-Biotics issued and sold 4,600,000 shares of its common stock at a price of US$15.00 per share. Hong Kong-based partner and Chairman of Asia Practice Group Simon Luk and New York-based partner Eric Cohen led the Winston’s team to handle this cross-border transaction.